Renoprotective effects of (+)-catechin in streptozotocin-induced diabetic rat model

详细信息	查看全文 | 推荐本文 |

• 作者：Sudha P. Chennasamudram^a ; Shashi Kudugunti^b ; Purushotham Reddy Boreddy^b ; Majid Y. Moridani^c ; Tetyana L. Vasylyeva^a ; ^{tetyana.vasylyeva@ttuhsc.edu}
• 关键词：Catechins ; ACEi ; Diabetic nephropathy ; Oxidative stress ; Rat
• 刊名：Nutrition Research
• 出版年：2012
• 期刊代码：123_02715317
• 类别：bio
• 出版时间：May, 2012
• 卷：32
• 期：5
• 页码：347-356
• 文件大小：930 K

摘要

Diabetic nephropathy is a complication of diabetes mellitus leading to end-stage renal disease. Oxidative stress and inflammation play a major role in the pathogenesis of diabetic nephropathy. Green tea, known for its antioxidant and anti-inflammatory properties, has been shown to be renoprotective. We hypothesized that (+)-catechin (CTN), a component of green tea, is responsible for the renoprotection. Our investigation of the therapeutic potential of CTN in streptozotocin-induced diabetic rats demonstrated for the first time that the effects of CTN treatment were comparable with the effects of an angiotensin-converting enzyme inhibitor (ACEi) enalapril for the treatment of albumin excretion. After 12 weeks of CTN treatment with 35 mg/d in the drinking water, urinary albumin excretion and plasma creatinine concentrations in all the diabetic treatment groups were reduced, compared with the diabetic group with no treatment. Urine creatinine and creatinine clearance were higher in diabetic groups treated with CTN and ACEi compared with the diabetic group with no treatment. Endothelin 1, lipid peroxidation, concentration of alanine transferase enzyme, and expression of fibronectin were lower in all the treatment groups compared with the diabetic group with no treatment. Concentrations of free thiols were higher in the CTN-treated group compared with the diabetic rats with no treatment. Our findings suggest that CTN has renoprotective properties comparable with ACEi, and coadministration of CTN and enalapril might be useful in reducing albumin excretion as well as improving endothelial function. (+)-Catechin might be successfully used in the future for clinical situations where ACEi is poorly tolerated or contraindicated.